AstraZeneca wins U.S. approval for hypertension pill Baxfendy

AstraZeneca won U.S. approval for Baxfendy, a new blood-pressure pill aimed at adults whose hypertension remains uncontrolled despite other medicines. The company says it is the first and only aldosterone synthase inhibitor cleared in the United States, a distinction that could give it a foothold in one of cardiology’s hardest-to-treat markets.

The drug is approved only as an add-on to other antihypertensive medications, not as a replacement for standard therapy. That matters because Baxfendy is entering a crowded field already built around diuretics, ACE inhibitors and other long-used drugs. Its selling point is different: it blocks aldosterone, a hormone that can drive blood pressure higher and raise the risk of heart and kidney complications. For patients who have already stacked multiple therapies without reaching control, AstraZeneca is pitching a new mechanism rather than another familiar pill.

The approval rested on the BaxHTN phase III trial, a multicenter, randomized, double-blind, placebo-controlled study in adults with uncontrolled or resistant hypertension. AstraZeneca said the 2 mg dose lowered seated systolic blood pressure by 15.7 mmHg from baseline and by 9.8 mmHg versus placebo-adjusted baseline after 12 weeks. The company said Baxfendy was generally well tolerated, with no unanticipated safety findings. AstraZeneca received FDA Priority Review for the application in December 2025 after positive BaxHTN results were announced in July 2025.

The market opportunity is large, but the eligible population is narrower than AstraZeneca’s blockbuster framing suggests. Hypertension affects about 1.4 billion people worldwide and nearly half of U.S. adults, around 120 million people, but Baxfendy is aimed at the subgroup whose blood pressure stays high despite treatment. AstraZeneca says about 50% of U.S. patients already taking multiple antihypertensive drugs still struggle with persistently elevated blood pressure, which gives the drug a meaningful clinical role if doctors adopt it quickly.

That adoption will depend on whether clinicians see Baxfendy as a practical next step for resistant cases, especially as the 2025 AHA/ACC multisociety guideline reaffirmed a goal below 130/80 mmHg. AstraZeneca, which acquired baxdrostat through its 2023 purchase of CinCor Pharma, has said the drug could eventually exceed $5 billion in peak annual sales. Hitting that mark will require more than approval alone. It will depend on how fast physicians move beyond older combinations and how often insurers and health systems make room for a first-in-class option in a market where millions still miss basic blood-pressure targets.